Lao Element Pharmaceuticals’ mechanism of action of lorlatinib

Lorlatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) positive as measured by an FDA-approved test.

The most common (incidence≥20%)adverse reactions and grade 3-4 laboratory abnormalities with lorlatinib are edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia, and cough.

Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1 as well as TYK1, FER, FPS, and FPS. Activities of n>TRKA, TRKB, TRKC, FAK, FAK2 and ACK. Lorlatinibhas shown activity in vitro against multiple mutated forms of the ALKenzyme, including some mutations detected in tumors undergoing disease progression with crizotinib and other ALK inhibitors. In mice implanted subcutaneously with tumors containing EML4 fusions harboring ALKvariant 1 or ALK mutations included in The overall antitumor activity of loratinib in in vivo models was dose-dependent and correlated with Related to the inhibition of ALK phosphorylation. The current retail price of generic drugs from 100mg30pills3 is about one thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about overseas high-quality drugs for you.